𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epidermal growth factor, renin, and protease in hormonally responsive duct cells of the mouse sublingual gland

✍ Scribed by Gresik, Edward W. ;Barka, Tibor


Publisher
John Wiley and Sons
Year
1983
Tongue
English
Weight
683 KB
Volume
205
Category
Article
ISSN
0003-276X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Immunocytochemical localization of nerve
✍ Gresik, E. W. ;Chung, K. W. ;Barka, T. ;Schenkein, I. πŸ“‚ Article πŸ“… 1980 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 490 KB πŸ‘ 1 views

## Abstract The submandibular glands of mice with testicular feminization (Tfm/Y) and their normal adult male littermates (Ta/Y) were studied by immunocytochemical techniques for the demonstration of epidermal growth factor (EGF), nerve growth factor (NGF), renin and protease A. In the glands of bo

Role of epidermal growth factor in the a
✍ David P. Ankrapp; Jessica M. Bennett; Sandra Z. Haslam πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 332 KB πŸ‘ 2 views

The purpose of the present studies was to investigate the role of epidermal growth factor (EGF) in the acquisition of estrogen (E) and progestin (P) responsiveness in the mouse mammary gland in vivo. Using the Elvax 40P implant technique to introduce bioactive molecules directly into the mammary gla

Identification and characterization of a
✍ Melissa A. Wilson; Susan A. Chrysogelos πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 198 KB

## Abstract The epidermal growth factor receptor (EGFR) exhibits an inverse correlation with estrogen receptor (ER) expression in the majority of breast cancers, predicting a poor response to endocrine therapy and poor survival rate. Inappropriate overexpression of EGFR in breast cancer is associat

Response to dual blockade of epidermal g
✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 332 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2